Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2022 | Physician perceptions of testing practices in patients with EGFR mutated NSCLC

Jens Samol, MD, Tan Tock Seng Hospital & Faculty Appointment at Johns Hopkins University, Tan Tock Seng, Singapore, talks on the physicians’ perceptions of testing practices in patients with early or advanced stage EGFR-mutated NSCLC. A questionnaire was sent out to various physicians’ globally to explore the differences in testing for EGFR mutations in adenocarcinomas, concluding that practices differ widely based on the availability of testing for mutations. Testing was noted to increase from earlier to later stages. However, there is a possibility for patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC) to be treated with adjuvant osimertinib, as investigated in the Phase III ADAURA (NCT02511106) trial. This interview took place during the virtual European Lung Cancer Congress 2022.